Literature DB >> 24528009

FOXA1: a promising prognostic marker in breast cancer.

Qing Hu1, Zhou Luo, Tao Xu, Jun-Ying Zhang, Ying Zhu, Wei-Xian Chen, Shan-Liang Zhong, Jian-Hua Zhao, Jin-Hai Tang.   

Abstract

Accurate diagnosis and proper monitoring of cancer patients remain important obstacles for successful cancer treatment. The search for cancer biomarkers can aid in more accurate prediction of clinical outcome and may also reveal novel predictive factors and therapeutic targets. One such prognostic marker seems to be FOXA1. Many studies have shown that FOXA1 is strongly expressed in a vast majority of cancers, including breast cancer, in which high expression is associated with a good prognosis. In this review, we summarize the role of this transcription factor in the development and prognosis of breast cancer in the hope of providing insights into utility of FOXA1 as a novel biomarker.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24528009     DOI: 10.7314/apjcp.2014.15.1.11

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  13 in total

1.  Foxa1 is essential for mammary duct formation.

Authors:  Yi Liu; Yongbing Zhao; Benjamin Skerry; Xiao Wang; Christelle Colin-Cassin; Derek C Radisky; Klaus H Kaestner; Zhaoyu Li
Journal:  Genesis       Date:  2016-03-29       Impact factor: 2.487

2.  Association of FOXA1 and EMT markers (Twist1 and E-cadherin) in breast cancer.

Authors:  Dorra BenAyed-Guerfali; Emna Dabbèche-Bouricha; Wajdi Ayadi; Fatma Trifa; Slim Charfi; Abdelmajid Khabir; Tahia Sellami-Boudawara; Raja Mokdad-Gargouri
Journal:  Mol Biol Rep       Date:  2019-04-02       Impact factor: 2.316

3.  FOXA1 transcriptionally up-regulates cyclin B1 expression to enhance chondrosarcoma progression.

Authors:  Zong-Shin Lin; Chiao-Chen Chung; Yu-Chia Liu; Tsung-Ming Chen; Yung-Luen Yu; Shao-Chun Wang; Ya-Huey Chen
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

4.  Clinicopathological significance of forkhead box protein A1 in breast cancer: A meta-analysis.

Authors:  Keli He; Hui Zeng; Xianqun Xu; Anling Li; Qing Cai; Xinghua Long
Journal:  Exp Ther Med       Date:  2016-04-06       Impact factor: 2.447

5.  Lack of both androgen receptor and forkhead box A1 (FOXA1) expression is a poor prognostic factor in estrogen receptor-positive breast cancers.

Authors:  Seho Park; Eunjin Koh; Ja Seung Koo; Seung Il Kim; Byeong-Woo Park; Kyung-Sup Kim
Journal:  Oncotarget       Date:  2017-09-15

6.  Gene Amplification-Driven Long Noncoding RNA SNHG17 Regulates Cell Proliferation and Migration in Human Non-Small-Cell Lung Cancer.

Authors:  Tianwei Xu; Shuai Yan; Lihua Jiang; Shanxun Yu; Tianyao Lei; Daolu Yang; Binbin Lu; Chenchen Wei; Erbao Zhang; Zhaoxia Wang
Journal:  Mol Ther Nucleic Acids       Date:  2019-06-20

7.  Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.

Authors:  Hakan Savlı; Sara Galimberti; Deniz Sünnetçi; Martina Canesastraro; Giuseppe Palumbo; Balint Nagy; Francesco Di Raimondo; Mario Petrini
Journal:  Turk J Haematol       Date:  2015-09       Impact factor: 1.831

8.  MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer.

Authors:  Ross M Drayton; Stefan Peter; Katie Myers; Saiful Miah; Ewa Dudziec; Helen E Bryant; James W F Catto
Journal:  Oncotarget       Date:  2014-08-15

9.  Impact of OGT deregulation on EZH2 target genes FOXA1 and FOXC1 expression in breast cancer cells.

Authors:  Ewa Forma; Paweł Jóźwiak; Piotr Ciesielski; Agnieszka Zaczek; Katarzyna Starska; Magdalena Bryś; Anna Krześlak
Journal:  PLoS One       Date:  2018-06-04       Impact factor: 3.240

10.  High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer.

Authors:  Heba Sheta; Amal Abd El Hafez; Maha Saif; Alyaa R Elsergany; Doaa Al Emam; Mahmoud Mohamed Abdelrazik
Journal:  Pathologica       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.